Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready
Apnimed Inc. (Delaware) has 7 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 6 distinct examiners and 3 distinct art units, indicating substantial examiner distribution with greater concentration at the art-unit level.
RAHMANI, NILOOFAR is the busiest examiner, with 2 pending matters. Counsel should combine centralized portfolio coordination with focused handling of the matters assigned to that examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (57%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 2 | 77.6% | -2.9% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709055 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | RAHMANI, NILOOFAR | — |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | — |
| 18548604 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708616 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | — |
| 18286399 | COMBINATION OF NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | MAHLUM, JONATHAN DAVIS | — |
| 18548604 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | ISMAIL, REHANA | — |
| 18271716 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1691 | 3 |
| 1625 | 3 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709055 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18708616 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | 1624 | §102§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18570673 | NOREPINEPHRINE REUPTAKE INHIBITORS FOR TREATING SLEEP APNEA | RAHMANI, NILOOFAR | 1691 | §103 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18286399 | COMBINATION OF NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | MAHLUM, JONATHAN DAVIS | 1625 | §103Other | Final Rejection | — | Pending | Oct 11, 2023 |
| 18548604 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | ISMAIL, REHANA | 1625 | §102§103Other | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18271716 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApnimed Inc. (Delaware) has 7 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Niloofar Rahmani has the most, with 2 of Apnimed Inc. (Delaware)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
